Valproic acid, produced by Lactobacillus acidophilus, binds to the GPR41/43 receptor on liver cell surfaces, inhibiting the oncogenic Rho-GTPase pathway and exhibiting protection against non-alcoholic fatty liver disease-related HCC [48]. This evidence concerns the gene FFAR3 and metabolic dysfunction-associated steatotic liver disease.